# SPMED

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spmed

- Industry: Pharmaceuticals
- Headquarters: Busan, South Korea
- Website: www.spmed.kr
- Total disclosed funding: $5.2M
- Latest round: Series A (Jul 21, 2021)
- Investors on record: 3

## About

Based in Busan, South Korea and founded in 2016, SPMED is a precision medicine bioventure company established by researchers with 20 years of experience in the field of drug genomics, led by Professor Jae-guk Shin of Inje University Hospital. In 2016, the company was selected as the 7th Busan Metropolitan City Startup Support Project by the Busan Economic Promotion Agency. The next year, 2017, its head office went under expansion and relocation followed by an affiliation as a research institute from the Ministry of Science's ICT and Future Planning. In 2019, SPMED signed a contract with designated hospitals for drug genetic testing (Essem Hospital, Busan Sahmyook Hospital) and the company joined the Genome Industry Association in the same year.

The company develops precision medicine based on genome, clinical information, living environment, and habit information.

## Funding rounds

- Series A, Jul 21, 2021, $5.2M — Korea Investment Partners, IMM Investment, Timefolio Asset Management

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series A
- Timefolio Asset Management — Series A